Effect of New Oral Anticoagulants Dabigatran and Rivaroxaban on Point of Care Coagulation Testing - an Ex-Vivo Study

Johann Wolfgang Goethe University Hospital34 enrolled

Overview

The purpose of this study is determine whether point of care coagulation testing is able to map the anticoagulatory effects of new oral anticoagulants dabigatran and rivaroxaban. Used as devices are thrombelastometry/-graphy (ROTEM, TEG)and multiple platelet function analyzer (Multiplate).

Patients receiving dabigatran or rivaroxaban in therapeutic doses are recruited. Blood will be taken twice in correlation to the time of drug intake (before and 3 hours after drug intake). The results of thrombelastometry/-graphy and multiple platelet function analyzer will be compared directly with the concentrations determined by plasma concentration assays.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Clot Formation and Platelet Aggregation in Point of Care Testing

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients receiving Dabigatran or Rivaroxaban * Adults \> 18 years Exclusion Criteria: * Patients receiving concomittantly inhibitors of platelet function * Renal insufficiency (Creatinine \> 1,5 mg/dl), Urea \> 80 mg/dl) * Hemodialysis * Hepatic Dysfunction (AST \> 30 U/l, ALT \> 30 U/l)

Locations (1)

University Hospital of University hospital of Frankfurt/Main, Department of Anesthesiology, Intensive-Care Medicine and Pain Therapy

Frankfurt am Main, Hesse, Germany

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.